TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
17.82
+0.11 (+0.62%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close17.71
Open17.85
Bid0.00 x 0
Ask0.00 x 0
Day's Range17.72 - 17.99
52 Week Range10.85 - 33.82
Volume8,379,213
Avg. Volume12,869,712
Market Cap18.121B
Beta1.02
PE Ratio (TTM)N/A
EPS (TTM)-16.26
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.29
Trade prices are not sourced from all markets
  • Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations
    Market Realist2 days ago

    Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations

    Jazz Pharmaceuticals (JAZZ) estimates that in fiscal 2018, its net revenue will be $1.86 billion–$1.93 billion. Its estimated GAAP (generally accepted accounting principles) gross margin is 93% for 2018.

  • Business Wire3 days ago

    Teva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare Partnership

    Teva Pharmaceutical Industries [NYSE and TASE: TEVA] has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC (Over The Counter) medicines. No significant (material) net financial transfer between Teva and P&G will result from the dissolution. PGT Healthcare has grown into a significant presence in over 50 countries, mainly in Europe and Asia, using market-leading brands such as Vick’s and ratiopharm.

  • Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio
    Market Realist3 days ago

    Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio

    In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $312.5 million compared to $291 million in 4Q16. In fiscal 2017, Xyrem reported revenues of $1.2 billion compared to $1.1 billion in 2016, which reflected a 7% growth on a YoY basis. Xyrem is used for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy.

  • Jazz Pharmaceuticals: How It’s Positioned before 1Q18
    Market Realist3 days ago

    Jazz Pharmaceuticals: How It’s Positioned before 1Q18

    In 4Q17, Jazz Pharmaceuticals (JAZZ) generated revenues of $436.4 million compared to $396.6 in 4Q16, which reflected a 10% growth on a YoY (year-over-year) basis and a 6% growth quarter-over-quarter.

  • Novartis’s 1Q18 Estimates: Expectations for Sandoz
    Market Realist4 days ago

    Novartis’s 1Q18 Estimates: Expectations for Sandoz

    Sandoz, the generics arm of Novartis (NVS), includes pharmaceuticals and biotechnological active substances in its portfolio. Sandoz is expected to report growth in operating revenue in 1Q18.

  • Business Wire5 days ago

    Teva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy of Neurology

    Teva Pharmaceutical Industries Ltd. today announced 38 scientific abstracts across five difficult-to-treat disorders of the central nervous system will be presented at the 70th Annual Meeting of the American Academy of Neurology in Los Angeles from April 21-27, 2018.

  • AbbVie’s Imbruvica in 4Q17 and Fiscal 2017
    Market Realist5 days ago

    AbbVie’s Imbruvica in 4Q17 and Fiscal 2017

    AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.

  • Israeli unions warn Teva Pharm over plan to close Ashdod plant
    Reuters7 days ago

    Israeli unions warn Teva Pharm over plan to close Ashdod plant

    Israel's main labour federation intends to strike or take legal action against Teva Pharmaceutical Industries if the drugmaker does not suspend a decision to close a plant in the port city of Ashdod, it said on Sunday. Debt-laden Teva , the world's largest generic drugmaker and Israel's biggest company, said last week that it would close the unprofitable plant in March 2019 after failing to find a buyer for the facility. In a letter to Teva's management, the Histadrut federation said the company's decision was contrary to a previous declaration that it would retain most of its activities in Israel.

  • Israeli unions warn Teva Pharm over plan to close Ashdod plant
    Reuters7 days ago

    Israeli unions warn Teva Pharm over plan to close Ashdod plant

    Israel's main labor federation intends to take labor or legal action against Teva Pharmaceutical Industries (Tel Aviv:TEVA.TA - News) if the drugmaker does not suspend a decision to close a plant in the Israeli port city of Ashdod, it said on Sunday. Debt-laden Teva (NYSE:TEVA - News), the world's largest generic drugmaker and Israel's biggest company, said last week that it would close the unprofitable plant in March 2019 after failing to find a buyer for the facility. In a letter to Teva's management, the Histadrut federation said the company's decision was contrary to a prior declaration that it would retain most of its activities in Israel.

  • 3 Top Healthcare Stocks to Buy in April
    Motley Fool8 days ago

    3 Top Healthcare Stocks to Buy in April

    April could be the perfect time to pick up shares in these top healthcare stocks.

  • Alexion to Acquire Wilson Therapeutics for $855 Million
    Market Realist8 days ago

    Alexion to Acquire Wilson Therapeutics for $855 Million

    On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.

  • Analyst Recommendations for Teva Pharmaceutical in April 2018
    Market Realist11 days ago

    Analyst Recommendations for Teva Pharmaceutical in April 2018

    In December 2017, the FDA accepted Teva Pharmaceutical Industries’ (TEVA) BLA (Biologics License Application) for fremanezumab for the preventive treatment of migraine. In February 2018, the European Medicines Agency accepted the MAA (Marketing Authorization Application) for fremanezumab for the treatment of adults with episodic and chronic migraine. In January 2018, the FDA approved Teva Pharmaceutical’s Trisenox and tretinoin combination therapy for the treatment of individuals with newly-diagnosed, low-risk APL (acute promyelocytic leukemia) with a presence of PML/RAR alpha gene expression.

  • A Look at Teva Pharmaceutical’s Specialty Medicines Segment
    Market Realist11 days ago

    A Look at Teva Pharmaceutical’s Specialty Medicines Segment

    In 4Q17, Teva Pharmaceutical Industries’ (TEVA) specialty medicines segment generated revenues of $1.8 billion compared to $2.2 billion in 4Q16. That was a 19% YoY (year-over-year) decline.

  • ACCESSWIRE11 days ago

    Today’s Research Reports on Stocks to Watch: Teva and Therapix

    NEW YORK, NY / ACCESSWIRE / April 10, 2018 / Shares of Therapix were popping on Monday after positive trial results about the company's proprietary cannabinoid product platform THX-IIO fell upon the eyes ...

  • Teva Pharmaceutical’s Generic Medicines Segment in 2017
    Market Realist12 days ago

    Teva Pharmaceutical’s Generic Medicines Segment in 2017

    In fiscal 2017, Teva Pharmaceutical Industries’ (TEVA) generic medicines segment reported revenues of $12.3 billion compared to $12 billion in 2016, which was a 2% YoY (year-over-year) growth.

  • Teva Pharmaceutical’s Performance in 4Q17 and 2017
    Market Realist12 days ago

    Teva Pharmaceutical’s Performance in 4Q17 and 2017

    In 4Q17, Teva Pharmaceutical Industries (TEVA) reported revenues of $5.5 billion compared to $6.5 billion in 4Q16. That’s a 16% growth on a YoY (year-over-year) basis and a 3% growth on a quarter-over-quarter basis.

  • Teva Pharm to close plant in Israel after no buyer found
    Reuters12 days ago

    Teva Pharm to close plant in Israel after no buyer found

    By Steven Scheer JERUSALEM (Reuters) - Debt-laden Teva Pharmaceutical Industries said on Monday it would close an unprofitable plant in the Israeli port city of Ashdod in March 2019 after failing to find a buyer for the facility. Teva, the world's largest generic drugmaker and Israel's biggest company, said in a statement half of the factory's 175 workers would lose their jobs in the coming months with the rest continuing to work until the plant closes. In December, Teva said it would cut 14,000 jobs - 25 percent of its global workforce - and close many plants as part of a restructuring aimed at helping to pay down debts.

  • Teva Pharm to close plant in Israel after no buyer found
    Reuters12 days ago

    Teva Pharm to close plant in Israel after no buyer found

    Debt-laden Teva Pharmaceutical Industries said on Monday it would close an unprofitable plant in the Israeli port city of Ashdod in March 2019 after failing to find a buyer for the facility. Teva, the world's largest generic drugmaker and Israel's biggest company, said in a statement half of the factory's 175 workers would lose their jobs in the coming months with the rest continuing to work until the plant closes. In December, Teva said it would cut 14,000 jobs - 25 percent of its global workforce - and close many plants as part of a restructuring aimed at helping to pay down debts.

  • ACCESSWIRE19 days ago

    Today’s Research Reports on Stocks to Watch: Alkermes and Teva

    NEW YORK, NY / ACCESSWIRE / April 3, 2018 / Shares of Alkermes plunged on Monday with the stock hitting lows it hasn't seen in 18 months. The stock crumbled after the FDA said it would not review the company's ...

  • How Did Sandoz Perform in 4Q17 and Fiscal 2017?
    Market Realist19 days ago

    How Did Sandoz Perform in 4Q17 and Fiscal 2017?

    How Is Novartis Positioned after 4Q17?

  • How Novartis’s Cardio-Metabolic and Neuroscience Segments Performed
    Market Realist20 days ago

    How Novartis’s Cardio-Metabolic and Neuroscience Segments Performed

    How Is Novartis Positioned after 4Q17?

  • How Bristol-Myers Squibb’s Virology Drugs Performed in 4Q17
    Market Realist23 days ago

    How Bristol-Myers Squibb’s Virology Drugs Performed in 4Q17

    What’s Behind Bristol-Myers Squibb’s Valuation

  • Teva Expects a Fall in Its Expenses and Cost Base in Fiscal 2018
    Market Realist25 days ago

    Teva Expects a Fall in Its Expenses and Cost Base in Fiscal 2018

    Recently, Teva Pharmaceutical (TEVA) has witnessed trouble in its business due to a number of company-specific and macroeconomic factors. The Copaxone sales decline due to generic competition, the pricing pressures in the market, and the impairments recently recorded by Teva are among the major factors triggering the company’s restructuring to recuperate the decline in its sales and earnings. For more information, read The Key Challenges Teva Pharmaceutical Is Facing.

  • GlobeNewswire25 days ago

    Analysis: Positioning to Benefit within PagSeguro Digital, Piedmont Office Realty Trust, Teva Pharmaceutical Industries, Obsidian Energy, HSBC Holdings plc, and ICICI Bank — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, March 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • A Look at Teva Pharmaceutical’s Fiscal 2018 Sales Guidance
    Market Realist26 days ago

    A Look at Teva Pharmaceutical’s Fiscal 2018 Sales Guidance

    Investor Update: How Is Teva's Restructuring Plan Progressing?